HOROMONAL ERECTILE DYSFUNCTION

Evaluation and Management
      Sexual interest and performance long have been associated with an adequate hormonal milieu, resulting in the indiscriminate administration of androgens to men with erectile dysfunction. Better understanding of penile physiology has shown that adequate sexual interest and erections can be maintained in the presence of diminished serum levels of testosterone. Nevertheless, hypogonadism affects sexual interest and erections adversely to variable degrees depending not only on the intensity of the deficiency but also on emotional and environmental factors and the degree of integrity of the neurovascular supply to the penis.
      The most convincing evidence of a positive correlation between the incidence and severity of erectile dysfunction and aging has been provided by the Massachusetts Male Aging Study (MMAS).
      • Feldman H.A.
      • Goldstein I.
      • Hartzichristou D.G.
      • et al.
      Impotence and its medical and psychosocial correlates: Results of the Massachusetts Male Aging Study.
      Although the aging process in men is an interindividual variable, profound hormonal alterations and a decrease in sexual performance can occur. These two truisms (i.e., aging men sustain erectile dysfunction, and testosterone decreases with age) are not necessarily related and should not be construed to imply that erectile failure is exclusively a consequence of endocrine changes. The MMAS was unable to link the coexistence of erectile dysfunction and a decrease in the serum levels of sex hormones, with the notable exception of a direct correlation between erectile shortcomings and a serum deficit in dehydroepiandrosterone (DHEA) and its sulfated form (DHEAS). To interpret this finding, it must be remembered that, although hypotestosteronemia and aging show marked differences among men, the association of low DHEA and advancing age exhibits a more predictable, constant, and profound association. It is likely that the correlation between the progressive decrease in DHEA levels, diminished erectile capacity, and advancing age is purely coincidental. The role of DHEA and DHEAS in sexual performance and desire has not been investigated thoroughly and remains an interesting and fertile area of research. The role of androgens in sexual function in general and in erectile physiology in particular is of fundamental importance. It is estimated that 1 in 200 men have abnormally low levels of testosterone, and that most of them are candidates for androgen supplementation therapy.
      Replacing testosterone in men.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      PDF Download and 24 Hours Online Access
      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Urologic Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Ansong K.S.
        • Punwaney R.B.
        An assessment of clinical relevance of testosterone level determination in the evaluation of men with low sexual drive.
        J Urol. 1999; 162: 719-721
        • Arver S.
        • Meikle A.W.
        • Dobbs A.S.
        • et al.
        Permeation enhanced testosterone transdermal systems in the treatment of male hypogonadism: Long term effects.
        J Endocrinol. 1996; 148: 254-259
        • Bagatell C.J.
        • Bremner W.J.
        Drug therapy: Androgens in men—uses and abuses.
        N Engl J Med. 1996; 334: 707-711
        • Crook D.
        Androgen therapy in the aging male: Assessing the effect on heart disease.
        Aging Male. 1999; 2: 151-156
        • Bancroft J.
        • Wu C.F.W.
        Changes in erectile responsiveness during androgen replacement therapy.
        Arch Sex Behav. 1983; 12: 59
        • Behere H.M.
        Prostate volume in treated and untreated hypogonadal men in comparison to age matched controls.
        Clin Endocrinol. 1994; 40: 341-346
        • Bhasin S.
        • Bremner W.J.
        Emerging issues in androgen replacement therapy.
        J Clin Endocrinol Metab. 1997; 82: 3-7
        • Bhasin S.
        • Tenover J.S.
        Sarcopenia: Issues in testosterone replacement of older men.
        J Clin Endocrinol Metab. 1997; 82: 1659-1660
        • Bhasin S.
        Androgen treatment of hypogonadal men.
        J Clin Endocrinol Metab. 1992; 74: 1221-1224
        • Bradwin S.W.
        • Swerdloff R.S.
        • Santen R.J.
        Androgens: Risks and benefits.
        J Clin Endocrinol Metab. 1991; 73: 4-7
        • Burris A.S.
        • Banks S.M.
        • Carter C.S.
        • et al.
        A long-term prospective study of the physiologic and behavioural effects of hormone replacement in untreated hypogonadal men.
        J Androl. 1992; 13: 297-304
        • Christiansen K.
        Behavioural correlates of testosterone..
        in: Nieschlan E. Behere H.E. Testosterone: Action, Deficiency, Substitution. Springer-Verlag, Berlin1998: 107-131
        • Cooper C.S.
        • Perry P.J.
        • Sparks A.E.
        • et al.
        Effects of exogenous testosterone on prostate volume, serum and semen prostate specific antigen levels in healthy young men.
        J Urol. 1998; 159: 441-443
        • Curran M.J.
        • Bihrle W.
        Dramatic raise in prostate specific antigen after androgen replacement in a hypogonadal man with occult adenocarcinoma of the prostate.
        Urology. 1999; 53: 423-424
        • De Sanctis V.
        • Vullo C.
        • Urso L.
        • et al.
        Clinical experience using Androderm testosterone transdermal system in hypogonadal adolescents and young men with beta-thalassemia major.
        J Pediatr Endocrinol Metab. 1999; 11: 891-900
        • Dobbs A.S.
        • Meikle A.W.
        • Arver S.
        • et al.
        Pharmacokinetics, efficacy and safety of permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men.
        J Clin Endocrinol Metab. 1999; 84: 3469-3478
        • Ehrenreich H.
        • Halaris A.
        • Ruether E.
        • et al.
        Psychoendocrine sequelae of chronic testosterone deficiency.
        J Psychiatr Res. 1999; 33: 379-387
        • Feldman H.A.
        • Goldstein I.
        • Hartzichristou D.G.
        • et al.
        Impotence and its medical and psychosocial correlates: Results of the Massachusetts Male Aging Study.
        J Urol. 1994; 151: 54-61
        • Grubb M.R.
        • Checkers D.
        • Malarkey W.B.
        Patients with primary hypothyroidism presenting as prolactinomas.
        Am J Med. 1987; 83: 765
        • Guay A.T.
        • Bansal S.
        • Hodge M.B.
        Possible hypothalamic impotence: Male counterpart to hypothalamic amenorrhea?.
        Urology. 1991; 38: 317-322
        • Guo C.-Y.
        • Jones T.H.
        • Eastell R.
        Treatment of isolated hypogonadotropic hypogonadism: Effect on bone mineral density and turnover.
        J Clin Endocrinol Metab. 1997; 82: 658-665
        • Handelsman D.J.
        • MacKey M.A.
        • Howe C.
        • et al.
        An analysis of testosterone implants for androgen replacement therapy.
        Clin Endocrinol. 1997; 47: 311-314
        • Hasin S.
        • Swerdlof R.S.
        • Steiner B.
        A biodegradable testosterone microcapsule formulation provides uniform eugonadal levels of testosterone for 10–11 weeks in hypogonadal men.
        J Clin Endocrinol Metab. 1992; 74: 75-79
        • Heaton J.P.W.
        • Adams M.A.
        • Morales A.
        A therapeutic taxonomy of treatments for erectile dysfunction: An evolutionary imperative.
        Int J Impot Res. 1997; 9: 115-121
        • Holmäng S.
        • Marin P.
        • Lindtstedt G.
        • et al.
        Effect of long term oral testosterone undecanoate treatment of prostate volume and serum prostate specific antigen in eugonadal middle-aged men.
        Prostate. 1993; 23: 99-106
        • Krauss D.J.
        • Taub H.A.
        • Lantiga L.J.
        Risk of blood volume changes in hypogonadal men treated with testosterone enanthate for erectile impotence.
        J Urol. 1991; 146: 1566-1570
        • Lledo-Garcia E.
        • Moncada I.
        • Saenz de I, Tejada
        An update in the physiology of erection..
        in: Morales A. Erectile Dysfunction—Issues in Current Pharmacology. Martin Dunitz, London1998: 1-26
        • Mauras N.
        • Hayes V.Y.
        • Vieira N.E.
        • et al.
        Profound hypogonadism has significant negative effects on calcium balance in males: A calcium kinetic study.
        J Bone Miner Res. 1999; 14: 577-582
        • Moilanen A.M.
        • Karvonen U.
        • Poukka H.
        • et al.
        A testis-specific androgen receptor coregulator that belongs to a novel family of nuclear proteins.
        J Biol Chem. 1999; 274: 3700-3704
        • Montague D.K.
        Editorial: Medical therapies for erectile dysfunction.
        J Urol. 1999; 162: 732
        • Morales A.
        • Baines J.
        • Ruijs A.
        • et al.
        Clinical practice guidelines for screening and monitoring male patients receiving testosterone supplementation therapy.
        Int J Impot Res. 1996; 8: 95
        • Morales A.
        • Connolly J.
        • Burr R.
        • et al.
        The use of radioactive phosphorous to treat bone pain in metastatic carcinoma of the prostate.
        Can Med Assoc J. 1970; 103: 372-373
        • Morales A.
        • Heaton J.P.W.
        • Johnston B.
        • et al.
        Oral and topical treatment of erectile dysfunction: Present and future.
        Urol Clin North Am. 1995; 22: 879-886
        • Morales A.
        • Heaton J.W.P.
        • Carson III, C.C.
        Andropause: A misnomer for a true clinical entity.
        J Urol. 2000; 163: 705
        • Morales A.
        • Johnston B.
        • Heaton J.P.W.
        • et al.
        Testosterone supplementation for hypogonadal impotence: Assessment of biochemical measurements and therapeutic outcomes.
        J Urol. 1997; 157: 849-854
        • Morley J.E.
        Clinical diagnosis of age-related testosterone deficiency.
        Aging Male. 2000; 3: 55
        • Negro-Vilar A.
        Selective androgen receptor modulators (SARMs): A novel approach to androgen therapy for the new millenium.
        J Clin Endocrinol Metab. 1999; 84: 3459-3462
        • Nickel J.C.
        • Morales A.
        • Condra M.
        • et al.
        Endocrine dysfunction in impotence: Incideence, significance and cost-effective screening.
        J Urol. 1984; 130: 40-43
        • Nieschlag E.
        • Behere H.M.
        Pharmacological and clinical uses of testosterone..
        in: Nieschlar A. Behere H.M. Testosterone: Action, Deficiency, Substitution. Springer-Verlag, Berlin1998: 294-321
        • Nomura A.
        • Heilrunn L.K.
        • Stemmermann G.N.
        • et al.
        Prediagnostic serum hormones and the risk of prostate cancer.
        Cancer Res. 1998; 48: 3515-3520
        • Ozata M.
        • Odabasi Z.
        • Caglayan S.
        • et al.
        Event related male potentials in male hypogonadism.
        J Endocrinol Invest. 1999; 22: 508-513
        • Phillips G.B.
        The association of hypotestosteronemia with coronary artery disease in men.
        Arterioscler Thromb. 1994; 14: 701-705
        • Quinton R.
        • Cheow H.K.
        • Tymms D.J.
        • et al.
        Kallman's syndrome: Is it always for life?.
        Clin Endocrinol (Oxf). 1999; 50: 481-485
      1. Replacing testosterone in men.
        Drug Ther Bull. 1999; 37: 3-6
        • Russell-Aulet M.
        • Jaffe C.A.
        • Demott-Frieberg R.
        • et al.
        In vivo semiquantification of hypothalamic growth hormone-releasing hormone (GHRH) output in humans: Evidence for relative GHRH deficiency in aging.
        J Clin Endocrinol Metab. 1999; 84: 3490
        • Sandbloom R.A.
        • Matsumoto A.M.
        • Schoene R.B.
        • et al.
        Obstructive sleep apnea syndrome induced by testosterone administration.
        N Engl J Med. 1983; 308: 508-510
        • Santamaria J.D.
        • Prior J.C.
        • Fleetham J.A.
        Reversible reproductice dysfunction in men with sleep apnea.
        Clin Endocrinol (Oxf). 1988; 28: 470
        • Sokol R.Z.
        • Palacios A.
        • Campfield L.A.
        Comparison of the kinetics of injectable testosterone in eugonadal and hypogonadal men.
        Fertil Steril. 1982; 37: 425-430
        • Sternbach H.
        Age associated testosterone decline in men: Clinical issues for psychiatry.
        Am J Psychiatr. 1998; 155: 1310-1314
        • Tannahill R.
        Sex in History. Stein and Day, New York1980: 69
        • Tenover J.L.
        Testosterone and the aging male.
        J Androl. 1997; 18: 103-106
        • Tenover J.L.
        Testosterone replacement therapy in older adult men.
        Int J Androl. 1999; 22: 300-306
        • Thompson W.O.
        Uses and abuses of the male sex hormone.
        JAMA. 1946; 132: 185-188
        • Uyanik B.S.
        • Ari Z.
        • Gumus B.
        • et al.
        Beneficial effects of testosterone undecanoate on the lipoprotein profiles in healthy elderly men.
        Jpn Heart J. 1997; 38: 73-77
        • Velhuis J.D.
        • Iranmanesh A.
        • Mulligan T.
        Disruption of the young-adult synchrony between luteinizing hormone release and oscillations in follicle-stimulating hormone, prolactin and nocturnal penile tumescence in healthy older men.
        Endocrinol Metab. 1999; 84: 3498-3505
        • Vermeulen A.
        • Stoica T.
        • Verdonck L.
        The apparent free testosterone concentration and index of androgenicity.
        J Clin Endocrinol Metab. 1971; 3: 759-767
        • Vermeulen A.
        • Verdonck L.
        • Kaufman J.M.
        A critical evaluation of simple methods for the estimation of free testosterone in serum.
        J Clin Endocrinol Metab. 1999; 84: 3666-3672
        • Vermeulen A.
        Androgens in the aging male.
        J Clin Endocrinol Metab. 1991; 73: 221-224
        • Wabg C.
        • Alexander G.
        • Berman N.
        • et al.
        Testosterone replacement therapy improves mood in hypogonadal men: A clinical research center study.
        J Clin Endocrinol Metab. 1996; 81: 3587-3593
        • Yates W.R.
        • Perry P.J.
        • MacIndoe J.
        • et al.
        Psychosexual effects of 3 doses of testosterone cycling in normal men.
        Biol Psychiatry. 1999; 45: 254-260
        • Zamuda J.M.
        • Cauley J.A.
        • Kriska A.
        Longitudinal relation between endogenous testosterone and cardiovascular disease risk factors in middle age men: A 13 year follow-up of former risk factor intervention trial participants.
        Am J Epidemiol. 1997; 146: 609-615